U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Ovarian Carcinoma

MedGen UID:
78865
•Concept ID:
C0278689
•
Neoplastic Process
Synonyms: Recurrent Carcinoma of Ovary; Recurrent Carcinoma of the Ovary; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Cancer of the Ovary; Recurrent Ovarian Cancer; Recurrent ovarian cancer; Recurrent Ovarian Epithelial Cancer; Relapsed Carcinoma of Ovary; Relapsed Carcinoma of the Ovary; Relapsed Epithelial Cancer of Ovary; Relapsed Epithelial Cancer of the Ovary; Relapsed ovarian cancer; Relapsed Ovarian Carcinoma; Relapsed Ovarian Epithelial Cancer
SNOMED CT: Relapsed ovarian cancer (461371000124103); Recurrent ovarian cancer (461371000124103)

Definition

The reemergence of ovarian carcinoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA
Gynecol Oncol 2021 Dec;163(3):490-497. Epub 2021 Sep 30 doi: 10.1016/j.ygyno.2021.08.030. PMID: 34602290
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy.
González-Martín A; GEICO Group
Int J Gynecol Cancer 2005 Nov-Dec;15 Suppl 3:241-6. doi: 10.1111/j.1525-1438.2005.00436.x. PMID: 16343239

Recent clinical studies

Etiology

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246

Diagnosis

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Therapy

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L
J Clin Oncol 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11 doi: 10.1200/JCO.21.01511. PMID: 35404684
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr
Gynecol Oncol 2021 Aug;162(2):345-352. Epub 2021 May 25 doi: 10.1016/j.ygyno.2021.05.015. PMID: 34045053Free PMC Article
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article

Prognosis

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa N, Emoto R, Matsui S, Kajiyama H
Int J Clin Oncol 2022 Oct;27(10):1660-1668. Epub 2022 Jul 30 doi: 10.1007/s10147-022-02214-9. PMID: 35906336
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ
Semin Oncol 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. PMID: 19332246

Clinical prediction guides

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B
EBioMedicine 2023 Mar;89:104477. Epub 2023 Feb 16 doi: 10.1016/j.ebiom.2023.104477. PMID: 36801617Free PMC Article
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa N, Emoto R, Matsui S, Kajiyama H
Int J Clin Oncol 2022 Oct;27(10):1660-1668. Epub 2022 Jul 30 doi: 10.1007/s10147-022-02214-9. PMID: 35906336
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A
Clin Oncol (R Coll Radiol) 2018 Aug;30(8):493-497. Epub 2018 May 7 doi: 10.1016/j.clon.2018.04.006. PMID: 29743148
Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis.
Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L
Int J Gynecol Cancer 2013 May;23(4):598-607. doi: 10.1097/IGC.0b013e31828a183c. PMID: 23502451

Recent systematic reviews

Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis.
Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V, Indini A, Aletti G, Raspagliesi F
Int J Gynecol Cancer 2016 Feb;26(2):371-80. doi: 10.1097/IGC.0000000000000597. PMID: 26588238
CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis.
Gu P, Pan LL, Wu SQ, Sun L, Huang G
Eur J Radiol 2009 Jul;71(1):164-74. Epub 2008 Apr 18 doi: 10.1016/j.ejrad.2008.02.019. PMID: 18378417

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...